Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2025-06-12 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
EHA 2025 SNT-5505 Interim Data Webinar Presentation 21 pages 5.4MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation of interim clinical trial data for a drug candidate (SNT-5505) targeting myelofibrosis, including study design, patient characteristics, safety, and efficacy results. It contains substantive data and analysis, including patient outcomes, adverse events, and biomarker responses. The document is dated June 2025 and references ongoing study progress and interim results. It is not a brief announcement or a regulatory filing, nor is it a transcript or a management change notice. The content aligns with an Interim / Quarterly Report (IR) as it provides comprehensive financial and clinical data for a period shorter than a full fiscal year, specifically interim clinical trial data. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2025-06-12 English
SNT-5505 awarded US FDA Fast Track designation 3 pages 212.1KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 10 June 2025 from Syntara Limited announcing that their lead candidate drug SNT-5505 has been granted Fast Track designation by the US FDA for treatment of myelofibrosis. The content focuses on the regulatory milestone, clinical trial progress, and company statements about the drug development. There are no financial statements, earnings data, or detailed financial analysis. The document is a public announcement of a regulatory update rather than a financial report or detailed investor presentation. It is not a report publication announcement since it does not mention an attached report or provide a link to a report. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about FDA designation and clinical progress, which does not fit into other more specific categories like earnings release, capital update, or management report.
2025-06-09 English
Application for quotation of securities - SNT 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used to apply for quotation of securities. It details the issuance and quotation of new securities resulting from the exercise of options or conversion of convertible securities. The document includes specifics such as the number of securities, issue date, and whether the securities are part of an employee incentive scheme. This type of document is a formal announcement related to capital changes, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about securities quotation. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is not merely a brief notice but a full application for quotation, supporting a high confidence score.
2025-06-09 English
Change in substantial holding 6 pages 620.8KB
Regulatory Filings Classification · 70% confidence The document text provided is almost entirely composed of placeholders indicating omitted pictures, with no visible textual content or explicit references to any report type, regulatory body, or financial data. The document length is 15,000 characters, which is substantial, but the actual content is not visible here. Given the lack of textual information, no specific report type can be identified. The document does not appear to be a short announcement or a certification letter, but since the content is not accessible, the safest classification is the fallback category for miscellaneous filings that do not fit other categories, which is Regulatory Filings (RNS).
2025-05-25 English
Change in substantial holding 5 pages 200.9KB
Regulatory Filings
2025-05-21 English
Investor Presentation 24 pages 1.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by the CEO of Syntara, a clinical stage drug developer, focusing on the company's investment highlights, clinical trial updates, scientific background, and management team. It includes forward-looking statements, financial information such as share price and market cap, detailed descriptions of clinical trials and drug candidates, and scientific data. The content is structured as a comprehensive investor presentation with slides and detailed explanations, rather than a formal regulatory filing, earnings release, or annual report. There is no indication that this is a transcript of a call, a voting result announcement, or a legal proceeding. The presence of forward-looking statements and detailed scientific and financial data aimed at investors strongly supports classification as an Investor Presentation (IP). The document length (15,000 characters) and depth of content also support this classification rather than a brief announcement or report publication notice.
2025-05-06 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.